血清高病毒载量和乙型肝炎发作孕妇的抗病毒治疗*

doi:10.3969/j.issn.1672-5069.2019.01.005

Abstract

Lin Su, Zhu Yueyong.. Antiviral therapy in pregnant women with high serum viremia or hepatitis B flare[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 13-16.

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[2] Giles ML,Visvanathan K,Lewin SR,et al.Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv,2012,67(1):37-44.
[3] Chang CY,Aziz N,Poongkunran M,et al.Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol,2016,111(10):1410-1415.
[4] Dionne-Odom J,Tita AT,Silverman NS.Hepatitis B in pregnancy screening,treatment,and prevention of vertical transmission. Am J Obstetr Gynecol,2016,214(1):6-14.
[5] Visvanathan K,Dusheiko G,Giles M,et al.Managing HBV in pregnancy. Prevention,prophylaxis,treatment and follow-up:position paper produced by Australian,UK and New Zealand key opinion leaders. Gut,2015,65(2):340-350.
[6] 丁洋,尤红,任红,等. 感染乙型肝炎病毒的育龄女性临床管理共识. 临床肝胆病杂志,2018,34(6):1176-1180.
[7] Lu Y,Zhu F,Liu J,et al.The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources:A large prospective cohort study in China. Vaccine,2017,35(48 Pt B):6627-6633.
[8] Wen W,Chang M,Zhao L,et al.Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. J Hepatol,2013,59(1):24-30.
[9] Brown RS Jr,McMahon BJ,Lok AS,et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy:A systematic review and meta-analysis. Hepatology,2016,63(1):319-333.
[10] 赵媛,曹耀章,房荣,等. 替比夫定对HBV高载量孕妇母婴传播阻断的疗效及安全性:一项随机对照研究. 实用肝脏病杂志,2017,20(2):157-160.
[11] Pan CQ,Duan Z,Dai E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med,2016,374(24):2324-2334.
[12] Han G,Cao M,Zhao W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol,2011,55(6):1215-1221.
[13] Zhang H,Pan CQ,Pang Q, et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology,2014,60(2):468-476.
[14] Pan CQ,Han GR,Jiang HX,et al.Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol,2012,10(5):520-526.
[15] Jourdain G,Ngo-Giang-Huong N,Harrison L,et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(10):911-923.
[16] Cheung KW,Seto MTY,Ng EHY.Tenofovir to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2349-2350.
[17] Gerlich W,Glebe D.Tenofovir topPrevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2349.
[18] Terrault NA,Feld JJ,Lok ASF.Tenofovir to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(24):2348-2349.
[19] Chen Z,Gu G,Bian Z,et al.Clinical course and perinatal transmission of chronic hepatitis B during pregnancy:A real-world prospective cohort study. J Infect,2017,75(2):146-154.
[20] Mugwanya K,Hendrix C,Mugo N,et al.Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women:A prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med,2016,13(9):e1002132.
[21] Ehrhardt S,Xie C,Guo N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate:a review of the evidence. Clin Infect Dis,2015,60(2):275-278.
[22] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10(1):1-98.
[23] Han GR,Jiang HX,Wang CM,et al.Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat,2017,24(6):514-521.
[24] Shang J,Wen Q,Wang CC,et al.Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy:Long-term follow-up. J Viral Hepat,2017,24(Suppl 1):43-48.
[25] Siberry GK,Jacobson DL,Kalkwarf HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis,2015,61(6):996-1003.
[26] Gibb DM,Kizito H,Russell EC,et al.Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. Plos Med,2012,9(5):e1001217.
[27] Terrault NA,Bzowej NH,Chang KM,et al.AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2016,63(1):261-283.
[28] Ofliver EAF.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[29] Sokal EM,Paganelli M,Wirth S,et al.Management of chronic hepatitis B in childhood:ESPGHAN clinical practice guidelines:consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology,Hepatology and Nutrition. J Hepatol,2013,59(4):814-829.

Antiviral therapy in pregnant women with high serum viremia or hepatitis B flare

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Tang Renyi, Hu Qunfeng, Peng Liqing.. Changes of serum lipids, liver function tests and estrogen levels in patients with intrahepatic cholestasis of pregnancy and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(6): 860-863.
[11]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[12]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[13]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[14]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[15]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.